Villalona-Calero MA - Search Results

1

Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.

Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff DD, Rowinsky E. Villalona-Calero MA, et al. J Clin Oncol. 1998 Aug;16(8):2770-9. doi: 10.1200/JCO.1998.16.8.2770. J Clin Oncol. 1998. PMID: 9704730 Clinical Trial.

2

Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.

Liu J, Amini A, Govindarajan A, Abuali T, Mambetsariev I, Massarelli E, Villaflor V, Villalona-Calero M, West H, Williams T, Salgia R. Liu J, et al. JCO Precis Oncol. 2023 Sep;7:e2200445. doi: 10.1200/PO.22.00445. JCO Precis Oncol. 2023. PMID: 37656950 Review.

3

Acute progranulocytic leukemia (APL): possible in vivo differentiation by granulocyte colony-stimulating factor (G-CSF).

Vaickus L, Villalona-Calero MA, Caligiuri T. Vaickus L, et al. Leukemia. 1993 Oct;7(10):1680-1. Leukemia. 1993. PMID: 7692195 No abstract available.

4

Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer.

Lu T, Ma R, Mansour AG, Bustillos C, Li Z, Li Z, Ma S, Teng KY, Chen H, Zhang J, Villalona-Calero MA, Caligiuri MA, Yu J. Lu T, et al. Among authors: villalona calero ma. Cancer Immunol Res. 2024 Jun 4;12(6):731-743. doi: 10.1158/2326-6066.CIR-23-0324. Cancer Immunol Res. 2024. PMID: 38572955 Free PMC article.

5

Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience.

Villalona-Calero MA, Malhotra J, Chung V, Xing Y, Gray SW, Hampel H, Gruber S, McDonnell K. Villalona-Calero MA, et al. J Clin Med. 2023 Jun 15;12(12):4061. doi: 10.3390/jcm12124061. J Clin Med. 2023. PMID: 37373756 Free PMC article.

6

New anticancer agents in clinical development.

Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. Eckardt J, et al. Oncology (Williston Park). 1995 Nov;9(11):1191-9. Oncology (Williston Park). 1995. PMID: 8703688 Review.

7

New anticancer agents in clinical development.

Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. Eckardt J, et al. Oncology (Williston Park). 1995 Dec;9(12):1321-8; 1331; discussion 1332-4. Oncology (Williston Park). 1995. PMID: 8771106 Review.

8

A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema.

Villalona-Calero MA, Eckardt J, Burris H, Kraynak M, Fields-Jones S, Bazan C, Lancaster J, Hander T, Goldblum R, Hammond L, Bari A, Drengler R, Rothenberg M, Hadovsky G, Von Hoff DD. Villalona-Calero MA, et al. Ann Oncol. 1998 Jan;9(1):71-7. doi: 10.1023/a:1008251426425. Ann Oncol. 1998. PMID: 9541686 Free article. Clinical Trial.

9

Alternative dosing schedules for irinotecan.

Rothenberg ML, Kuhn JG, Schaaf LJ, Drengler RL, Eckhardt SG, Villalona-Calero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Von Hoff DD. Rothenberg ML, et al. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):68-71. Oncology (Williston Park). 1998. PMID: 9726095 Free article. Review.

10

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.

Rothenberg ML, Sharma A, Weiss GR, Villalona-Calero MA, Eckardt JR, Aylesworth C, Kraynak MA, Rinaldi DA, Rodriguez GI, Burris HA 3rd, Eckhardt SG, Stephens CD, Forral K, Nicol SJ, Von Hoff DD. Rothenberg ML, et al. Ann Oncol. 1998 Jul;9(7):733-8. doi: 10.1023/a:1008286908930. Ann Oncol. 1998. PMID: 9739439 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters